Filing Overview
The provided filing is Aileron Therapeutics, Inc.’s Form 10-Q for the quarter ended September 30, 2022, filed November 1, 2022. This differs from the request metadata, which identifies Rein Therapeutics, Inc.; investors should verify the issuer identity. Aileron is a clinical-stage oncology company developing ALRN-6924, an MDM2/MDMX inhibitor intended to protect healthy cells from chemotherapy in patients with p53-mutated cancers.
Financial Condition and Results
| Metric | Three months ended September 30, 2022 | Nine months ended September 30, 2022 | Comparable period |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Research and development expense | $4.2 million | $15.6 million | $4.3 million and $12.4 million, respectively |
| General and administrative expense | $2.2 million | $7.4 million | $2.5 million and $7.3 million, respectively |
| Net loss | $6.4 million | $22.8 million | $6.7 million and $19.4 million, respectively |
| Net loss per share | $0.07 | $0.25 | $0.07 and $0.22, respectively |
| Cash used in operating activities | Not provided for the quarter | $20.5 million | $17.5 million |
| Cash, cash equivalents and investments | $25.5 million at September 30, 2022 | $45.9 million at December 31, 2021 |
The company had no product revenue and remains loss-making. Operating expenses increased the nine-month loss, with research and development representing approximately 68% of operating expenses. Operating and net profit margins are not meaningful because revenue was zero. Accumulated deficit was $268.2 million at September 30, 2022.
Total assets were $27.2 million and total liabilities were $4.5 million. The filing reports no material debt outstanding; the prior Paycheck Protection Program loan was forgiven in 2021. Current liabilities were $4.5 million, including $3.5 million of accrued expenses. Stockholders’ equity was $22.7 million.
Material Changes Versus Prior Period
- For the quarter, research and development expense declined by $0.04 million and general and administrative expense declined by $0.3 million, reducing the net loss by $0.3 million to $6.4 million.
- For the first nine months, research and development expense increased $3.1 million to $15.6 million, primarily from higher breast cancer trial spending, manufacturing costs for ALRN-6924 and related research.
- Nine-month general and administrative expense was essentially flat, increasing $0.04 million.
- Nine-month net loss increased $3.4 million, from $19.4 million to $22.8 million.
- Operating cash burn increased $3.0 million year over year to $20.5 million.
- Investments declined from $42.3 million at December 31, 2021 to $20.6 million at September 30, 2022, while cash and cash equivalents increased from $3.6 million to $4.8 million. Investment maturities and sales funded operations; no equity financing occurred during the nine months.
Clinical Outlook, Liquidity and Risks
- The company stopped further enrollment in its Phase 1b NSCLC trial after interim data from the first 20 patients and redirected resources to the Phase 1b breast cancer trial.
- The breast cancer trial was modified to improve the opportunity to demonstrate protection from severe neutropenia, alopecia and other chemotherapy toxicities. The trial may enroll up to 24 patients.
- Management planned initial breast cancer data for the fourth quarter of 2022, interim data on 12 patients in the second quarter of 2023 and topline results from 20 patients in the third quarter of 2023.
- Based on its operating plan, management expected $25.5 million of cash, cash equivalents and investments at September 30, 2022 to fund operating expenses through the first quarter of 2024. This estimate is subject to trial timing, spending and financing assumptions.
- The company expects continuing losses and will require additional capital to complete development or commercialize ALRN-6924. Potential sources include equity offerings, debt, collaborations, licensing transactions or other strategic alternatives.
- The company had not regained compliance with Nasdaq’s $1.00 minimum bid-price requirement and intended to effect a reverse stock split before the December 5, 2022 compliance date. Delisting could reduce liquidity and impair access to capital.
- Key risks include failure of the breast cancer trial, patient enrollment delays, clinical and regulatory uncertainty, dependence on third-party manufacturers, COVID-19-related disruptions, additional financing risk and potential dilution from future equity issuance.
- Under its license agreements, the company could owe future milestone payments of up to $7.7 million per licensed therapeutic product to Harvard and Dana-Farber and up to $6.4 million per licensed product to Umicore, plus royalties. No milestone liabilities were recorded because achievement was not considered probable.
Investor Verification Checklist
- Confirm that the filing belongs to Aileron Therapeutics, Inc., not Rein Therapeutics, Inc.
- Verify subsequent clinical results from the Phase 1b breast cancer trial and whether the stated 2022–2023 milestones occurred.
- Verify Nasdaq listing compliance, any reverse stock split and the company’s current trading status.
- Assess actual cash burn and remaining liquidity against the projected first-quarter 2024 funding runway.
- Review subsequent equity, debt, collaboration or strategic transactions and related shareholder dilution.
- Review the NSCLC trial discontinuation rationale and whether the breast cancer program supports continued development of ALRN-6924.